Predict your next investment

HEALTHCARE | Drug Discovery
pranabio.com

See what CB Insights has to offer

Founded Year

1997

Stage

PIPE | IPO

About Prana Biotechnology

Prana's lead candidate, PBT434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain.

Prana Biotechnology Headquarter Location

Level 3, 460 Bourke Street

Melbourne, Victoria, 3000,

Australia

+61 (0)3 9349 4906

Latest Prana Biotechnology News

Key Vendors of Huntingtons Disease Therapeutics Market: Alnylam Pharmaceuticals, Intellect …

Jul 27, 2020

Auspex Pharmaceuticals, Alnylam Pharmaceuticals, Intellect Neurosciences Incorporation, H. Lundbeck, Prana Biotechnology Limited, Raptor … Welcome to the home of information resources for AI and ML. We hope you find this site useful. Feel free to give us feedback. Copyright © 2020 Informed AI Group Ltd - Neurons.AI - The home of AI information resources This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Prana Biotechnology Patents

Prana Biotechnology has filed 5 patents.

The 3 most popular patent topics include:

  • Membrane biology
  • Neurological disorders
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/24/2020

5/18/2021

Trifluoromethyl compounds, Neurological disorders, Zinc compounds, V8SuperTourer drivers, Membrane biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/24/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/18/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Trifluoromethyl compounds, Neurological disorders, Zinc compounds, V8SuperTourer drivers, Membrane biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.